The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV-Reference-Cited by-同舟云学术

The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV

Published:2015-11-03 Issue:3 Volume:73 Page:329-348
ISSN:1077-5587
Container-title:Medical Care Research and Review
language:en
Short-container-title:Med Care Res Rev

Author:

Snider Julia Thornton¹,Goldman Dana P.²,Rosenblatt Lisa³,Seekins Daniel³,Juday Timothy⁴,Sanchez Yuri⁴,Wu Yanyu¹,Peneva Desi¹,Romley John A.²

Affiliation:

1. Precision Health Economics, Los Angeles, CA, USA

2. University of Southern California, Los Angeles, CA, USA

3. Bristol-Myers Squibb, Plainsboro, NJ, USA

4. AbbVie, Chicago, IL, USA

Abstract

We investigated the effect of changes to state AIDS Drug Assistance Programs (ADAP) policies, which govern access to antiretroviral therapy (ART), on clinical and economic outcomes among low-income people living with HIV/AIDS. Retrospective analyses of ART access were conducted on state ADAP policies, using data from ADAP Monitoring Reports and Kaiser Family Foundation from 2006 to 2010. We found stricter eligibility requirements reduce the number of HIV-positive individuals with ART access through ADAP, and decreased ART use increases mortality by 2.67 quality-adjusted life years (QALYs) per beneficiary. If the ADAP income eligibility cutoff were decreased by 50 percentage points in each state, 4,626 individuals would lose ART access nationwide. Based on a $22,143 cost/QALY, this policy would save $274 million in health care expenditures (2012 dollars), but result in 12,352 QALYs lost, valued at $1.2 billion. Therefore, states should exercise caution in restricting programs that increase ART access for low-income people living with HIV/AIDS.

Publisher

SAGE Publications

Subject

Health Policy

Link

http://journals.sagepub.com/doi/pdf/10.1177/1077558715614479

Reference46 articles.

1. The relationship between HAART use and employment for HIV-positive individuals: an empirical analysis and policy outlook

2. The link between public and private insurance and HIV-related mortality

3. What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?

4. Cost-Effectiveness of Nucleoside Reverse Transcriptase Inhibitor Pairs in Efavirenz-Based Regimens for Treatment-Naïve Adults with HIV Infection in the United States

5. The Interaction of Public and Private Insurance: Medicaid and the Long-Term Care Insurance Market

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intersectionality-informed analysis of durable viral suppression disparities in people with HIV;AIDS;2023-04-05

2. Economic benefits of the United States’ AIDS drug assistance Program: A systematic review of cost analyses to guide research and policy priorities;Preventive Medicine Reports;2022-10

3. Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018;Annals of Epidemiology;2020-05

4. Long-Term Individual and Population Consequences of Early-Life Access to Health Insurance;SSRN Electronic Journal;2016